Drugs and patents in ATC class B01 - ANTITHROMBOTIC AGENTS

Last updated: June 20, 2026

ecutive summary
ATC class B01 (antithrombotic agents) is a mix of entrenched, liquid-expired small-molecule brands and protected, still-commercialized direct oral anticoagulants (DOACs) plus antiplatelet regimens. Market structure is driven by (1) indication stacking across AF, VTE treatment and prophylaxis, and ACS/stroke prevention; (2) compound and formulation/process patent estates that extend exclusivity even after core active-ingredient losses; and (3) regulatory exclusivity and Paragraph IV litigation that can delay generic and biosimilar-like substitution for complex oral and supportive delivery products. The patent landscape is most concentrated around factor Xa inhibitors (apixaban, rivaroxaban, edoxaban) and factor IIa inhibitors (dabigatran), with parallel IP layers in antiplatelets (notably P2Y12 inhibitors and antiplatelet combinations) and injectables (heparins and synthetic anticoagulants), where manufacturing and method-of-use claims often matter as much as drug substance claims.

Market dynamics and patent landscape for ATC B01 antithrombotic agents

ATC B01 spans anticoagulants, antiplatelets, and related agents used for thrombosis and prevention of ischemic events. The practical patent impact in B01 is less about class-wide protection and more about brand-level estates where multiple patent types overlap:

Drug substance (API) patents: typically expire earlier than regulatory/market exclusivity layers.
Crystalline form, polymorph, salt, solvates: can extend generic entry for specific solids and rework the “what is protected” question.
Formulation patents: coatings, absorption modifiers, bioavailability windows, excipient systems, and manufacturing controls.
Method-of-use patents: dose regimens, patient subgroups, renal-adjusted strategies, and indication-specific steps.
Manufacturing/process patents: can create IP barriers even if the generic can source or recreate the API.
Regulatory exclusivity: data exclusivity, orphan exclusivity (when applicable), and listed-exclusivity blocks.

Because B01 drugs are often used chronically, even short delays translate into meaningful revenue exposure and leverage during settlement-driven “carve-outs” or delayed launches.

Which B01 antithrombotic drugs have the strongest patent estates right now?

Featured-snippet answer: DOACs dominate B01 patent strategy because they combine expensive clinical differentiation with dense patenting around solid forms, formulation, and dosing/renal adjustment. The most IP-intensive estates are typically apixaban, rivaroxaban, edoxaban, dabigatran, and major antiplatelet regimens, where formulation and method-of-use claims can still constrain “skinny-label” generics.

DOACs: why the patent estate stays relevant after API expiry

DOAC generics can face three recurring IP challenges:

Formulation constraints
- For dabigatran specifically, there is a long-running history of IP around capsule form and absorption control, which directly maps to what ANDA applicants must prove they do not infringe.
Polymorph/crystal and solid-state
- Many generic entries hinge on whether the ANDA uses a protected solid form or violates a claim targeting it.
Method-of-use and dosing regimen claims
- Even if the generic is “biosimilar-like” equivalent in pharmacokinetics, a claim can still be asserted if the proposed label supports a protected regimen in a protected subgroup.

Antiplatelets: what tends to be patent-heavy

In the ATC B01 antiplatelet segment, patent density is commonly concentrated in:

P2Y12 inhibitors (and later-generation modifications)
Combinations and dosing schedules
Patient stratification (high-risk subgroups)

How does the patent landscape differ between anticoagulants and antiplatelets in ATC B01?

Featured-snippet answer: Anticoagulants in B01 (especially DOACs) tend to have patent estates anchored in solid-state and formulation. Antiplatelets often show more method-of-use and combination regimen leverage, with additional patents around dose timing and switching.

Anticoagulants (B01A/B01AE/B01AF style coverage)

Typical IP blockers include:

crystallinity/polymorph
modified release or GI targeting (where applicable)
specific dosing steps for renal impairment and bridging strategies

Antiplatelets (B01AC/B01AD/B01AE style coverage)

Typical IP blockers include:

combination regimens (dual/triple therapy steps)
treatment sequencing and patient subgroup protocols

When do major B01 antithrombotic drugs lose exclusivity, and what drives launch timing?

Featured-snippet answer: Launch timing in B01 is driven by the latest “cliff” among API expiry, formulation/polymorph claim expiry, listed-exclusivity expiration, and any ongoing Paragraph IV litigation. In practice, the “earliest generic date” is often not the “first-to-market” date.

Core drivers of entry timing in B01

Patent expiry + 180-day exclusivity (for first Paragraph IV filer)
Settlement agreements that set delayed launch dates or market share-based carve-outs
Risk of launch design-arounds (different polymorph/formulation that must still be bioequivalent)
Labeling constraints due to “carve-out” settlements or non-infringement positions

B01-specific dynamics that matter

Chronic indications create a “hold-up” risk: generics try to enter at scale, but courts and FDA labeling decisions can constrain early adoption.
In DOACs, renal impairment labels and dosing details frequently become the center of method-of-use disputes.

How many patents cover DOACs like apixaban, rivaroxaban, edoxaban, and dabigatran?

Featured-snippet answer: Coverage is typically multi-layered and can reach dozens of relevant US patents per branded product when including formulation and method-of-use claims that appear on the Orange Book and in litigation.

Patent estate composition (what usually appears)

API compound and process patents
solid-state and polymorph
capsule/tablet coating formulation
dissolution/absorption control claims
method-of-use claims tied to indication and dosing strategies
manufacturing controls (impurity profiles, steps)

What patents protect apixaban, and how do they affect generic entry risks?

Featured-snippet answer: Generic entry risks for apixaban are usually most acute around solid-state/formulation claims and method-of-use/dosing claims that map to label language.

Key infringement vectors in apixaban generic Paragraph IV filings

whether the ANDA uses a protected solid form
whether the formulation infringes claims on excipient system/coating/release profile
whether the proposed label covers a protected dosing step or subgroup

What patents protect rivaroxaban, and how do they shape ANDA strategy?

Featured-snippet answer: For rivaroxaban, patent constraints typically center on formulation and dosing regimen claims plus process elements that can be tied to product equivalence.

Design-around pathways

different polymorph or manufacturing route
formulation changes that maintain bioequivalence while avoiding formulation claim elements
label carve-outs aligned to settlement positions or non-infringement stances

What patents protect edoxaban, and which claim types are usually litigated?

Featured-snippet answer: Edoxaban’s litigation pattern is commonly linked to solid-state/formulation and any method-of-use claims asserted around anticoagulation regimens.

Practical ANDA risk

Even when API claims are easier to clear, generic applicants can still face delay if:

a formulation claim is found not easily design-aroundable, or
method-of-use language overlaps with broad label submissions.

What patents protect dabigatran, and why are formulation and delivery system claims central?

Featured-snippet answer: Dabigatran has long-running patent pressure around oral delivery form and absorption control, making formulation and capsule-related claims a frequent battleground.

Why delivery system matters for infringement

generic equivalence is not only “same API,” but also “same clinical exposure,” which pushes applicants to preserve absorption profiles.
that can collide with patented excipient systems, coatings, and solid-form attributes.

What is the Orange Book status of key B01 antithrombotic drugs?

Featured-snippet answer: The Orange Book status for B01 generics cannot be summarized accurately class-wide because each branded product has unique listed patents and exclusivities by NDA.

(Only deliverable with product-level Orange Book data; producing class-only statements would be incomplete and error-prone.)

What Paragraph IV challenges drive the B01 antithrombotic litigation landscape?

Featured-snippet answer: Paragraph IV challenges in B01 are concentrated around DOACs and high-volume antiplatelets, where first-filer incentives and settlement economics make disputes high-stakes.

Typical litigation themes

Non-infringement by polymorph/formulation redesign
Invalidity based on anticipation/obviousness arguments against formulation and method-of-use claims
“Carve-out” settlements that narrow the generic label to avoid direct infringement

Settlement mechanics that affect market

Common settlement outcomes include:

delayed launch date tied to the latest-to-expire asserted patent
agreed label modifications or dosing restrictions
geographic or product-form limitations in some agreements

Which companies are challenging B01 antithrombotic patents with Paragraph IV filings?

Featured-snippet answer: In B01, challenges are typically filed by a small set of large generic manufacturers and later entrants seeking 180-day exclusivity or follow-on market share, while brand owners respond with infringement and injunction strategies.

(Deliverable requires named case mapping to specific ANDAs/Orange Book listings; class-wide company identification would not be accurate.)

Biosimilar risk: are there biosimilars in ATC B01 antithrombotic agents?

Featured-snippet answer: B01 includes biologics mainly in the broader sense of anticoagulant agents used in practice, but biosimilar-style substitutability is not the central exclusivity mechanism for B01 compared with small-molecule ANDA-based generics in DOAC and antiplatelet categories.

What actually drives substitution

For most mainstream B01 drugs, substitution is governed by:

ANDA pathways (small molecules)
patent carve-outs and label design
FDA bioequivalence and listed-patent obstacles

How do formulation patents affect tablet and capsule generic approval in B01?

Featured-snippet answer: Formulation patents can block approval or delay market entry by forcing ANDAs into narrow non-infringement or “switch” strategies (different excipients, coatings, solid forms, or manufacturing steps).

Common formulation claim types in oral antithrombotics

coating compositions and thickness-related parameters
dissolution profile targets
excipient systems that influence absorption
manufacturing conditions that define impurity profiles

How do method-of-use patents affect B01 dosing and label carve-outs?

Featured-snippet answer: Method-of-use patents constrain the generic’s ability to market the same therapeutic instructions. Courts or settlements can lead to label carve-outs where a generic omits protected steps, even if the drug substance is cleared.

Method-of-use pressure points

dose adjustments by renal function
switching from bridging therapies
indication-specific regimens in AF and VTE cohorts

What commercial metrics matter most for B01 antithrombotic patent value?

Featured-snippet answer: B01 patent value tracks to (1) patient-years on therapy, (2) penetration into high-volume indications (AF stroke prevention and VTE treatment/prophylaxis), and (3) time-to-entry after the last exclusivity/patent barrier.

Revenue exposure that follows patent cliffs

A broad label and large eligible population increases the cost of delay.
multiple indications create multiple “risk windows” for launch and label design.
payor formularies accelerate market share once a generic is cleared, increasing the downside of protracted litigation.

Which B01 antithrombotic generics are at highest risk of delayed entry?

Featured-snippet answer: Highest delay risk is associated with drugs where the latest asserted patents are typically formulation/polymorph/method-of-use and where settlements have historically shifted entry timelines.

(Accurate, product-specific ranking requires case-by-case Orange Book and litigation data.)

Key comparisons: which antithrombotics have the most IP friction, and why?

Featured-snippet answer: Among widely used oral antithrombotics, DOACs typically show higher IP friction than older agents because modern designs have layered patenting around delivery and dosing nuance.

Comparison matrix (structure-level, not case-specific)

Drug segment	Typical dominant patent types	Main generic entry barrier	Market lever
DOACs (factor Xa/IIa inhibitors)	solid-state, formulation, dosing method-of-use	formulation/polymorph non-infringement and label carve-outs	chronic high-volume adoption
Antiplatelets (P2Y12 and regimens)	method-of-use, combination steps, dosing strategies	label scope and protected regimen steps	acute and chronic secondary prevention
Heparins/LMWH/synthetic anticoagulants	process/manufacturing controls	manufacturing-specific IP and equivalence constraints	hospital channel penetration

Regulatory pathway: how does FDA approval intersect with B01 patent strategy?

Featured-snippet answer: FDA does not adjudicate infringement, but ANDA Paragraph IV certification and Orange Book-listed patents determine whether approval results in an immediate launch or triggers automatic stays and litigation.

What matters in B01 ANDAs

Paragraph IV vs Paragraph III certifications
whether the ANDA is approved but delayed due to a stay
whether the label is carved out to avoid infringement after settlements

Key Takeaways

B01 is patent-concentrated at the product level, especially in DOACs where solid-state, formulation, and method-of-use claims sustain exclusivity beyond API expiry.
Launch timing is a function of the last blocking patent plus regulatory/listed-exclusivity and litigation posture, not just the drug substance patent.
Formulation and delivery system patents are frequent flashpoints for oral anticoagulants; generic success often depends on design-around viability without losing bioequivalence.
Method-of-use patents can limit generic labels through court or settlement outcomes, preserving brand revenue even after certain patents expire.
Commercial value correlates with indication breadth and patient-years on therapy, making B01 patent cliffs high-impact for both brands and generics.

FAQs

How do Orange Book listed patents determine whether a B01 generic can launch immediately after FDA approval?
What claim elements in DOAC formulation patents most often drive non-infringement disputes in Paragraph IV cases?
How do settlements in B01 litigation typically affect generic label scope for AF and VTE indications?
What regulatory exclusivities can extend B01 brand protection beyond the latest drug-substance patent expiration?
Which B01 dosing regimens are most commonly targeted by method-of-use patents in anticoagulant disputes?

References

FDA Orange Book (Drug Products Approved by FDA). U.S. Food and Drug Administration.
Drug Competition Action Plan (DCAP) and Orange Book listing and certification framework. U.S. Food and Drug Administration.
21 U.S.C. §355(j) Paragraph IV certification provisions (Hatch-Waxman framework). U.S. Government.

Subclasses in ATC: B01 - ANTITHROMBOTIC AGENTS